Vivos Therapeutics, Inc. VVOS
Regular-session close
After hours · Nov 20, 7:46 PM ET
- YTD
- -97.34%
- 1 year
- -97.45%
5D -0.0124 (-13.11%)
- Market cap
- 1.83M
- Revenue (ttm)
- 14.02M
- Profit margin
- -85.90%
- EPS (ttm)
- -1.35
- Shares out
- 4.84M
- Forward P/E
- -9.31
- YTD return
- -97.34%
- 1-year return
- -97.45%
- Volume
- 1.44M
- Avg volume
- 14.42M
- Open
- 0.0535
- Previous close
- 0.0569
- Day's range
- 0.0501 – 0.0568
- 52-week range
- 0.0501 – 2.69
- Beta
- 7.68
- Price target
- 6.30 (+11566.7%)
Key statistics
- 50-day average
- 3.32
- 200-day average
- 2.88
- Enterprise value
- 4.52M
- Price / sales
- 1.77
- Price / book
- 22.86
- Revenue growth
- 19.40%
- Free cash flow
- -8.90M
- Total cash
- 6.90M
- Total debt
- 1.76M
- Return on equity
- -284.96%
- Short % of float
- 2.01%
Fundamental scorecard
6 of 25 checks passed on VVOS’s reported financials
6of 25 checks passed
- Value 2 of 5
- Growth 3 of 5
- Profitability 1 of 5
- Financial health 0 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -0.70 | -0.40 | +0.30 | +42.86% |
| Aug 14, 2024 | Jun 1, 2024 | 0.00 | -0.60 | — | — |
| Aug 14, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| May 14, 2024 | Mar 1, 2024 | 0.00 | -1.63 | — | — |
| May 14, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| Mar 28, 2024 | Dec 1, 2023 | 0.00 | -3.05 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 20, 2024 | Ascendiant Capital | reit | Buy | Buy |
| Nov 19, 2024 | Alliance Global Partners | main | Buy | Buy |
| Aug 20, 2024 | Ascendiant Capital | main | Buy | Buy |
About Vivos Therapeutics, Inc.
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- vivos.com
News
12 Health Care Stocks Moving In Thursday's Intraday Session
Vivos Therapeutics Q3 Earnings Call Highlights
Vivos Therapeutics, Inc. (VVOS) Q3 2026 Earnings Call Prepared Remarks Transcript Reported Earlier, Vivos Therapeutics Q3 EPS $(0.07) Beats $(0.42) Estimate, Sales $6.414M Beat $5.937M Estimate
Vivos Therapeutics, Inc. (VVOS) Reports Q3 Loss, Beats Revenue Estimates
Vivos Therapeutics Reports Third Quarter 2026 Financial Results and Provides Operational Update
Why 3M Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Your note
Sign in to keep a note on VVOS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| HUNTSMAN RONALD KIRK | Chief Executive Officer | Purchase | Jun 19, 2023 | 1,826,520 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Strategic Wealth Investment Group, LLC | 2.07% | 100,000 | 512.00K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.60% | 28,802 | 147.47K | Sep 29, 2024 |
| OMERS Administration Corporation | 0.52% | 25,000 | 128.00K | Sep 29, 2024 |
| Commonwealth Equity Services, LLC | 0.43% | 21,000 | 107.52K | Sep 29, 2024 |
| Sabby Management, LLC | 0.42% | 20,502 | 104.97K | Sep 29, 2024 |
| Two Sigma Investments, LP | 0.42% | 20,482 | 104.87K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.38% | 18,247 | 93.42K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.22% | 10,579 | 54.16K | Sep 29, 2024 |
| Fidelity Total Market Index Fund | 0.12% | 5,825 | 29.82K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.12% | 5,667 | 29.02K | Oct 30, 2024 |
